BRIEF published on 12/11/2025 at 07:05, 7 days 13 hours ago BioVersys lance un essai de phase 3 pour le BV100 et fait le point sur ses progrès commerciaux. Introduction En Bourse BioVersys Résistance Aux Médicaments BV100 Phase 3 Recherche Antibactérienne
BRIEF published on 12/11/2025 at 07:05, 7 days 13 hours ago BioVersys Initiates Phase 3 Trial for BV100 and Updates Business Progress IPO Drug Resistance BioVersys BV100 Phase 3 Antibacterial Research
PRESS RELEASE published on 12/11/2025 at 07:00, 7 days 13 hours ago BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update BioVersys AG initiates BV100 Phase 3 study for ventilator-associated bacterial pneumonia, achieving significant milestones in 2025 and upcoming key events in 2026 Clinical Trials Biopharmaceutical BioVersys AG BV100 Phase 3 Ventilator Associated Bacterial Pneumonia
BRIEF published on 11/10/2025 at 07:05, 1 month 8 days ago L'étude de phase 2B BV100 de BioVersys est prévue pour l'Asie Essai De Phase 2b Résistance Aux Médicaments BioVersys BV100 Financement Wellcome Réseau ADVANCE-ID
BRIEF published on 11/10/2025 at 07:05, 1 month 8 days ago BioVersys' BV100 Phase 2B Study Set for Asia Phase 2B Trial Drug Resistance BioVersys BV100 Wellcome Funding ADVANCE-ID Network
PRESS RELEASE published on 11/10/2025 at 07:00, 1 month 8 days ago BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network. BioVersys AG leads Phase 2 trial for innovative antibacterial product BV100 Phase 2b Clinical Trial BV100 BioVersys Wellcome Funded Trial Network
BRIEF published on 11/06/2025 at 07:05, 1 month 12 days ago BioVersys Advances BV100 Clinical Trials in China Clinical Trials BV100 BioVersys MDR Bacteria Acinetobacter
BRIEF published on 11/06/2025 at 07:05, 1 month 12 days ago BioVersys fait progresser les essais cliniques du BV100 en Chine Essais Cliniques BV100 BioVersys Bactéries Multirésistantes Acinetobacter
PRESS RELEASE published on 11/06/2025 at 07:00, 1 month 12 days ago Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA BioVersys announces the dosing of the first subject in a Phase 1 clinical trial with BV100 in China. BV100 targets MDR hospital infections caused by Acinetobacter baumannii Phase 1 Clinical Trial BV100 BioVersys MDR Bacteria Acinetobacter Baumannii
BRIEF published on 11/05/2025 at 07:05, 1 month 13 days ago BioVersys to Present at Stifel 2025 Annual Healthcare Conference New York City Healthcare Conference Clinical Developments BioVersys Multi-drug Resistant Bacteria
Published on 12/18/2025 at 15:00, 5 hours 20 minutes ago Vox Royalty Acquires Feasibilty-Stage Stockman Copper-Gold Royalty in Australia
Published on 12/18/2025 at 14:31, 5 hours 49 minutes ago Worksport Reports Highest Monthly Revenue in Company History
Published on 12/18/2025 at 14:00, 6 hours 20 minutes ago Route1 Announces Provisional Patent Application
Published on 12/18/2025 at 14:00, 6 hours 20 minutes ago LQR House Announces $6.52 Million Registered Direct Offering
Published on 12/18/2025 at 20:09, 11 minutes ago EQS-Adhoc: The Grounds Real Estate Development AG: Conversion of the EUR 17 million bond issued in 2023/2024 into a hybrid bond
Published on 12/18/2025 at 19:30, 50 minutes ago Prodware: COMMUNIQUE DU 18 DECEMBRE 2025 RELATIF A LA MISE A DISPOSITION DE LA NOTE EN REPONSE ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES DANS LE CADRE DE L’OFFRE PUBLIQUE DE RETRAIT
Published on 12/18/2025 at 19:30, 50 minutes ago Prodware: COMMUNIQUE DU 18 DECEMBRE 2025 RELATIF A LA MISE A DISPOSITION DE LA NOTE D’INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES , NOTAMMENT JURIDIQUES, FINANCIERE DE PHAST INVEST
Published on 12/18/2025 at 18:48, 1 hour 32 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 12/18/2025 at 18:45, 1 hour 35 minutes ago PATRIMOINE ET COMMERCE: PROJET D’AUGMENTATIONS DE CAPITAL DE PATRIMOINE & COMMERCE D’UN MONTANT DE 30 MILLIONS D’EUROS
Published on 12/18/2025 at 18:30, 1 hour 50 minutes ago Schneider Electric completes transaction to acquire remaining 35% stake in existing Indian JV
Published on 12/18/2025 at 18:30, 1 hour 50 minutes ago Schneider Electric finalise l’opération d’acquisition des 35% restants du capital de sa JV existante en Inde
Published on 12/18/2025 at 17:45, 2 hours 35 minutes ago Cie du Bois Sauvage: Vernietiging eigen aandelen
Published on 12/18/2025 at 17:45, 2 hours 35 minutes ago Damartex réaffirme son éligibilité au PEA-PME
Published on 12/18/2025 at 17:45, 2 hours 35 minutes ago Cie du Bois Sauvage : Cancellation of own shares
